EUCTR2007-000743-95-GB进行中（未招募）1 期
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECURE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Completion of 12 month treatment period of studies CRFB002A2302 (EXCITE) or -CRFB002A2303 (SUSTAIN) • Patient consent will be required to be enrolled
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concurrent participation in another clinical trial, i.e. use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
研究者
相似试验
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.MedDRA version: 9.1Level: LLTClassification code 10060837Term: Choroidal neovascularizationEUCTR2007-000743-95-NLovartis Pharma200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREEUCTR2007-000743-95-BEovartis Pharma Services AG200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.EUCTR2007-000743-95-HUovartis Pharma Services AG200
进行中（未招募）
不适用
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) - SECUREStudy population will consist of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who received treatment in either of the two ongoing ranibizumab studies RFB002A2302 (EXCITE) or RFB002A2303 (SUSTAIN). It is estimated that approximately 200 patients will be screened and assigned to treatment from approximately 40 centers in Europe.EUCTR2007-000743-95-PTovartis Pharma Services AG200
尚未招募
4 期
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)subfoveal choroidal neovascularization secondary to age-related macular degeneration10047060macular degenerationNL-OMON31158ovartis18